tbuckley/cabot-search huggingface dataset:
Prognostic Implications Of Abnormal Bone Marrow Lesions In The Appendicular Skeleton Detected By Whole-Body Multidetector CT: Comparison With 18f-FDG PET-CT
Authors: Yuki Nishida, Hiroki Sugihara, Masayuki Yamakura, Masami Takeuchi, Dai Chihara, Toshihiro O'uchi, Kosei Matsue
Journal: Blood (2013)
Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer
Authors: Tijana Borovski, Thomas T Vellinga, Jamila Laoukili, Evan E Santo, Szabolcs Fatrai, Susanne van Schelven, Andre Verheem, Dieuwke L Marvin, Inge Ubink, Inne H M Borel Rinkes, Onno Kranenburg
Journal: Gut (2016)

<h3>Background and aim</h3> Colorectal cancer (CRC) remains one of the leading causes of cancer-related death. Novel therapeutics are urgently needed, especially for tumours with activating mutations in <i>KRAS</i> (∼40%). Here we investigated the role of RAF1 in CRC, as a potential, novel target. <h3>Methods</h3> Colonosphere cultures were established from human tumour specimens obtained from patients who underwent colon or liver resection for primary or metastatic adenocarcinoma. The role of RAF1 was tested by generating knockdowns (KDs) using three independent shRNA constructs or by using RAF1-kinase inhibitor GW5074. Clone-initiating and tumour-initiating capacities were assessed by single-cell cloning and injecting CRC cells into immune-deficient mice. Expression of tight junction (TJ) proteins, localisation of polarity proteins and activation of MEK-ERK pathway was analysed by western blot, immunohistochemistry and immunofluorescence. <h3>Results</h3> KD or pharmacological inhibition of RAF1 significantly decreased clone-forming and tumour-forming capacity of all CRC cultures tested, including <i>KRAS</i>-mutants. This was not due to cytotoxicity but, at least in part, to differentiation of tumour cells into goblet-like cells. Inhibition of RAF1-kinase activity restored apicobasal polarity and the formation of TJs in vitro and in vivo<i>,</i> without reducing MEK-ERK phosphorylation. MEK-inhibition failed to restore polarity and TJs. Moreover, RAF1-impaired tumours were characterised by normalised tissue architecture. <h3>Conclusions</h3> RAF1 plays a critical role in maintaining the transformed phenotype of CRC cells, including those with mutated <i>KRAS</i>. The effects of RAF1 are kinase-dependent, but MEK-independent. Despite the lack of activating mutations in RAF1, its kinase domain is an attractive therapeutic target for CRC.
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer: A retrospective analysis.
Authors: H. Prenen, R. Geva, H. Piessevaux, S. Tejpar, C. Verslype, J. Vannoote, L. Mortier, E. Van Cutsem
Journal: Journal of Clinical Oncology (2011)

e14095 Background: The combination of chemotherapy and bevacizumab (beva), a monoclonal antibody targeting VEGF, is consistently being used as first- and second-line treatment in patients with metastatic colorectal cancer (mCRC). There is little data on activity of beva in advanced lines. The aim of this retrospective single center study is to evaluate the activity of beva combined with chemotherapy in patients with beva-naïve chemorefractory mCRC. Methods: Forty six consecutive patients treated in the University Hospital Gasthuisberg Leuven (Belgium) receiving beva in advanced lines following failure of conventional chemotherapy were included in this study. All patients failed under a chemotherapy with fluoropyrimidines plus irinotecan and/or oxaliplatin and/or cetuximab and received bevacizumab (5mg/kg) in combination with either FOLFOX or FOLFIRI. Tumor response was assessed by central review by use of RECIST guidelines; PFS and OS were calculated since start of treatment with beva. Results: Beva plus chemotherapy was used in third line in eight (17.4%) patients and in fourth line or more in the other 38 patients (82.6%). All patients previously failed irinotecan based chemotherapy, 44 (95.7%) failed oxaliplatin based regimens and 40 (87%) failed treatment with cetuximab. Median time on treatment since diagnosis of metastatic disease was 34.7 months. Beva was given in combination with irinotecan based chemotherapy in 36 patients while 9 patients received it in combination with oxaliplatin based chemotherapy and 1 patient in combination with single agent 5-FU. Objective response was demonstrated in 10 patients (21.7%) and disease control in 38 (82.6%) with a median PFS of 8.9 months and a median OS of 13.8 months. Only 4 patients experienced grade 3 and above bevacizumab related toxicity; in two patients with very extensive lung metastasis hemoptysis resulted in death. Conclusions: Taking into account the retrospective nature of the study which can influence the selection of patients, bevacizumab given in advanced lines after failure of conventional chemotherapy and anti-EGFR agents in beva-naïve patients can result in high disease control rates in selected patients.
Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).
Authors: Manasa Tatipalli, Xuyang Song, Min Pak, Carlos Chavez, Meina Liang, Hong Lu, Martin Schwickart, Joyson Joseph Karakunnel, Paul B. Robbins, Xiaoping Jin, Ashok Kumar Gupta, Lorin Roskos, Rajesh Narwal
Journal: Journal of Clinical Oncology (2015)

e14010 Background: MEDI4736 is a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD-80 with high affinity and selectivity. Tremelimumab is a selective human IgG2 mAb inhibitor of CTLA-4 that promotes T-cell activity though CTLA-4 inhibition. Combination of anti-PD-L1 and anti-CTLA-4 provides blockade of non-redundant pathways and potential for enhanced biological activity. The primary objectives of this analysis were to assess the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MEDI4736 in combination with tremelimumab in patients with NSCLC. Methods: Data were collected from a phase 1b study (NCT02000947) designed to evaluate safety and tolerability of MEDI4736 in combination with tremelimumab following 3.0, 10, 15 and 20 mg/kg every 4 weeks (Q4W)/every 2 weeks (Q2W) MEDI4736 and 1, 3 and 10 mg/kg Q4W tremelimumab. PK (n = 51), soluble PD-L1 (sPD-L1; n = 50), and anti-drug antibody (ADA; n = 53) data were available following MEDI4736. Tremelimumab PK (n = 26) and ADA (n = 53) data were also available. Data analysis was performed using Phoenix WinNonlin and GraphPad Prism software. Results: An approximately dose proportional increase in PK exposure of both MEDI4736 and tremelimumab was observed over the dose range of 3 to 20 mg/kg MEDI4736 and 1 to 10 mg/kg tremelimumab. Accumulation in PK of both MEDI4736 and tremelimumab was observed following repeated dosing. The observed PK exposures of MEDI4736 and tremelimumab following combination were in line with respective monotherapy data, indicating no PK interaction. Only 2 of 53 subjects (both at 15 mg/kg MEDI4736 + 1 mg/kg tremelimumab) were ADA positive for either anti-MEDI4736 or anti-tremelimumab antibodies post treatment. Following MEDI4736 in combination with tremelimumab, complete sPD-L1 suppression was observed in all subjects over the dose range of 3 to 20 mg/kg. Conclusions: MEDI4736 and tremelimumab exhibited dose-proportional PK exposures and were in line with other monotherapy studies. Low incidence of ADA was observed. Complete sPD-L1 suppression was observed throughout the dosing interval in all subjects. Clinical trial information: NCT02000947.
Performance in real life of the European Network on Drug Allergy algorithm in immediate reactions to beta‐lactam antibiotics
Authors: E. Moreno, E. Laffond, F. Muñoz‐Bellido, M. T. Gracia, E. Macías, A. Moreno, I. Dávila
Journal: Allergy (2016)

European Network on Drug Allergy (ENDA) has proposed an algorithm for diagnosing immediate beta-lactam (BL) allergy. We evaluated its performance in real life. During 1994-2014, 1779 patients with suspected immediate reactions to BL were evaluated following ENDA's short diagnostic algorithm. Five hundred and nine patients (28.6%) were diagnosed of BL hypersensitivity. Of them, 457 (25.7%) were at first evaluation [403 by skin tests (ST), 12 by positive IgE and 42 by controlled provocation tests (CPT)]. At second evaluation (SE), 52 additional patients (10.2% of allergic patients) were diagnosed, [50 (2.8%) by ST and 2 (0.1%) by CPT]. Time between reaction and study was significantly longer in patients diagnosed at SE (median 5 vs 42 months; IQR 34 vs 170; P < 0.0001). Anaphylaxis was significantly associated with a diagnosis at SE. European Network on Drug Allergy/EAACI protocol was appropriate and safe when evaluating BL immediate reactions. Re-evaluation should be performed, particularly when anaphylaxis and long interval to diagnosis are present.
Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): A metanalysis of randomized clinical trials (RCTs).
Authors: Giuseppe Lombardi, Ardi Pambuku, Luisa Bellu, Miriam Farina, Giovanna Pintacuda, Vittorina Zagonel
Journal: Journal of Clinical Oncology (2016)

e13501 Background: GBMs are highly vascularized tumors and various ADs have been investigated in clinical trials showing unclear results. We performed this metanalysis to evaluate the effectiveness of ADs, in terms of progression-free survival (PFS) and overall survival (OS), as first or second-line therapy and their association with chemotherapy in GBM PTS Methods: the authors searched relevant published and unpublished RCTs analyzing ADs versus chemotherapy in GBM PTS from 2000 to January 2016 in MEDLINE, WEB of SCIENCE, ASCO, ESMO and SNO databases Results: sixteen RCTs (9 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) were identified including 4566 PTS. All trials showed no improvement in OS with a pooled HR of 1.02 (95% CI 0.93-1.1; p = 0.7). The use of bevacizumab (BEV) did not improve OS; indeed, the pooled HR for OS for BEV studies (9 studies, 2752 PTS) was 0.98 (95% CI 0.89-1.08; p = 0.7); 6 RCTs (2084 PTS) analyzed BEV as first-line and the pooled HR for OS was 1.02 (95% CI 0.88-1.19; p = 0.8); 3 RCTs studied BEV as second-line therapy and the pooled HR for OS was 0.95 (95% CI 0.77-1.17; p = 0.6). No improvement of OS was shown when BEV was associated with chemotherapy (2588 PTS) with a pooled HR of 0.99 (95% CI 0.88-1.11; p = 0.8). Seven RCTs with a different AD demonstrating no improvement of OS versus standard treatment with a pooled HR of 1.05 (95% CI 0.89-1.23; p = 0.5). 14 RCTs (4349 PTS) were analyzed for PFS and the use of ADs showed a statistically longer PFS with a pooled HR of 0.73 (95% CI 0.62-0.86;p < 0.01); However, among ADs, only bevacizumab (2752 PTS) demonstrated an improvement of PFS; indeed, the pooled HR for PFS for BEV studies was significant at HR = 0.6 (95% CI 0.5-0.7; p < 0.01), both alone (HR = 0.6; CI 95% 0.44-0.82; p < 0.01) or in combination to CT (HR = 0.6; 95% CI 0.4-0.7;p < 0.01), both as first-line treatment (HR = 0.65; 95% CI 0.52-0.83; p < 0.01) or in recurrent disease (HR = 0.51; 95% CI 0.43-0.61; p < 0.01). Conclusions: ADs did not improve OS in GBM PTS, both as first or second-line treatment. Among ADs, only BEV demonstrated a PFS benefit both as single agent or in combination with chemotherapy, both as first or second-line treatment
A phase II study utilizing oxaliplatin and docetaxel in androgen independent prostate cancer in men treated with up to two prior chemotherapy regimens
Authors: T. M. Feinstein, D. M. Friedland, K. E. McIntire, S. A. Jacobs, W. A. Ferri, M. F. Earle, K. D. Hyoung, L. M. Brown, G. S. Chatta
Journal: Journal of Clinical Oncology (2006)

14580 Background: Second line treatment of androgen independent prostate cancer (AIPC) is unsatisfactory. Single agent docetaxel has demonstrated survival benefit in AIPC. In a phase-I study utilizing oxaliplatin at the University of Pittsburgh (UP), two patients with AIPC experienced a substantial and durable reduction in PSA. Thus, we hypothesised that a combination of docetaxel and oxaliplatin may be synergistic in AIPC. Methods: This single arm phase II trial commenced in June 2005, with the objectives of evaluating PSA response rates, progression free survival, and the toxicity (tolerance/safety) of the regimen. Using Simon stage II design, a total of 37 patients (pts) with AIPC will be accrued. To date, 20 men have been enrolled: median age 67 yrs (56–84); 9 patients being chemo-naïve and 11 having received prior chemotherapy. Treatment consisted of docetaxel (60 mg/m 2 ) and oxaliplatin (110 mg/m 2 ), infused every 21 days. Follow-up assessments (every two cycles) include serum PSA and imaging studies. Results: 14 of 20 men have completed at least two cycles and are evaluable. In the chemo-naïve subset (n = 8), the average pre-treatment PSA was 312.8 ± 275.8 ng/ml, with 3 of 8 pts experiencing &gt; 50% reduction in PSA and 2 of 8 pts with &gt; 25% reduction. In pts with prior chemotherapy (n = 6), the average pre-treatment PSA was 1194.4 ± 1777.8 ng/ml, with 3 of 6 pts experiencing &gt; 50% reduction in PSA and 1 of 6 pts with &gt; 25% reduction. 4 of 8 men with measurable soft tissue disease had a partial response. There were &lt; 7% grade 3/4 adverse events (AEs). Treatment-related AEs include: neutropenia (41%), thrombocytopenia (11.8%) and anemia (5.9%). Non-hematologic toxicity included neuropathy (53%) diarrhea (47%), nausea (41%) fatigue (76%) and anorexia (29.4%). Conclusions: The combination of oxaliplatin and doxetaxel is well tolerated in patients with AIPC, and has significant activity even in patients with prior exposure to chemotherapy. The study continues to accrue pts, and the results will be updated at presentation. [Table: see text]
A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)
Authors: Paul G. Richardson, Craig Hofmeister, Noopur S. Raje, David Siegel, Sagar Lonial, Jacob P. Laubach, Yvonne A Efebera, David H. Vesole, Ajay K Nooka, Jacalyn Rosenblatt, Mohamed H Zaki, Jennifer Herring, Yan Li, Sheetal Shah, Min S Chen, Kenneth C Anderson
Journal: Blood (2015)
Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation
Authors: Feras Alfraih, Naheed Alam, Anna Lambie, Vikas Gupta, Dennis Dong Hwan Kim, John Kuruvilla, Jeffrey H. Lipton, Matthew D. Seftel, Jieun Uhm, David Loach, Hans A. Messner
Journal: Blood (2014)
Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus
Authors: Li-dan Zhao, Di Liang, Xiang-ni Wu, Yang Li, Jing-wen Niu, Chen Zhou, Li Wang, Hua Chen, Wen-jie Zheng, Yun-yun Fei, Fu-lin Tang, Yong-zhe Li, Feng-chun Zhang, Wei He, Xue-tao Cao, Xuan Zhang
Journal: Cellular and Molecular Immunology (2016)
Elevated mRNA Expression of FGF2 and TGFB1 Genes in Myelofibrosis and Essential Thrombocythemia Patients
Authors: Daniela Prudente Teixeira Nunes, Luciene Terezina Lima, Guilherme Wataru Gomes, Maria de Lourdes L. F. Chauffaille, Maria Regina Regis Silva, Cesar Cilento Ponce, Marcelo Cliquet, Marcos Tadeu Santos, Elvira M Guerra-Shinohara
Journal: Blood (2014)
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle as second-line treatment for advanced or recurrent gastric cancer.
Authors: K. Chin, K. Kato, T. Yoshikawa, K. Yamaguchi, T. Esaki, Y. Tsuji, K. Sakai, M. Kimura, R. Ikeda, Y. Matsumura
Journal: Journal of Clinical Oncology (2010)

4041
Disagreement in the interpretation of the admission electrocardiogram in acute coronary syndromes and association with clinical outcome: Real-world insights from GRACE
Authors: SG Goodman, AT Yan, J Allegrone, J Lopez-Sendon, CB Granger, JM Gore, A Budaj, AA Georgescu, Q Hassan, J Luchansky, Frans Van de Werf
Journal: Journal of the American College of Cardiology (2005)
Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.
Authors: Marie O'Farrell, Richard Ventura, Albert Tai, Jeffrey W Tyner, Marc M Loriaux, Daruka Mahadevan, Carla Morales, S. David Brown, David J Matthews
Journal: Blood (2012)
molecular Epidemiology Of Hepatitis C Virus Genotype 5a In France (a Multicentre Study Anrs) : 1046
Authors: Henquell Cecile, Julien Guglielmini, Jannick Verbeeck, Jean-Luc Bailly, Marc Van Ranst, Karine Randl, Gilles Bommelaer, Helene Peigue-Lafeuille, Armand Abergel
Journal: Hepatology (2010)
CCGs must engage with public on potential service closures, says new guidance
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Clinical Commissioning Groups (CCGs) in England must engage with the public, clinicians, and politicians as early as possible when taking potentially controversial decisions such as closing local services, new guidance has advised.

Commissioners should also ensure that “tough decisions” about funding, prioritisation, and possible closures are safe, cost effective, and backed by robust evidence, the report from NHS Clinical Commissioners, the membership body for CCGs, said.1

The group said it had issued the guidance as local health bodies in England were going through a period of major change that made hard choices “increasingly inevitable.” It said that ongoing financial pressures and the development of 44 System and Transformation …
Rho Gtpase Cdc42 Is Essential for Endothelial Niche Maintenance in the Bone Marrow and Hematopoiesis
Authors: Yuxin Feng, Xuan Zhou, Wei Liu, Fukun Guo, Ming Liu, Leesa Sampson, Li-Ru You, Chia-Yi Kuan, Yi Zheng
Journal: Blood (2012)
Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial
Authors: Francesca Gay, Valeria Magarotto, Maria Teresa Petrucci, Francesco Di Raimondo, Luděk Pour, Tommaso Caravita, Vlastimil Scudla, Anna Maria Cafro, Anna Marina Liberati, Stefano Spada, Maisnar Vladimir, Norbert Pescosta, Roberto Ria, Massimo Offidani, Sara Bringhen, Annalisa Bernardini, Francesca Patriarca, Paolo Corradini, Roberto Foà, Nicola Cascavilla, Lucio Catalano, Andrew Spencer, Roman Hajek, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2015)
Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma.
Authors: S. Wilgenhof, A. M. Van Nuffel, D. Benteyn, J. Corthals, C. Heirman, L. Pierret, A. De Coninck, A. Bonehill, K. Thielemans, B. Neyns
Journal: Journal of Clinical Oncology (2010)

8547 Background: mRNA electroporated autologous DC are being developed as therapeutic cancer vaccines. Potential advantages include the presentation of all potential tumor antigen confined epitopes by the patient's own HLA-molecules and improved immunostimulatory capacity of the DC-vaccine. Methods: Immature DCs (derived from PBMC obtained by leucapheresis and cultured for 6 days in IL-4/GM-CSF supplemented medium) were electroporated with synthetic mRNA encoding a fusion protein between MAGE-A1, -A3, -C2, Tyrosinase, MelanA/MART-1 or gp100, and DC-LAMP, and poly I:poly C12U or mRNA encoding TLR-4, CD70 and CD40L. DC (12.5 106/antigen) were administered by 4 to 6 ID-injections q2w, and q8w thereafter. Interferon alfa-2b (IFN-a2b, 5 MIU TIW) was initiated at progression, concomitant or following the 4th vaccine in cohort 1, 2, 3, and 4. Results: 70 melanoma pts were recruited between 06/′05 and 06/′09: 44M/26F; med age: 46y (27–75); AJCC stage III: 30, IV-M1a: 8, - M1b: 6, -M1c: 26; WHO-PS 0: 46, 1: 19, 2: 5; serum LDH nl.: 58, -elevated: 12; ulcerated primary: 13, -not ulcerated: 11, -unknown: 46. A total of 466 DC- vaccines were administered (median/pt: 6, range 2-18). Vaccine related AEs: gr 2 local injection site reactions: all pts; gr 2 fever/lethargy: 3 pts; skin depigmentation: 13 pts. Median RFS for pts without evaluable disease (ED): 23 mths (95% CI 12-33); 3 pts have died, mOS has not been reached. The tumor response among 40 pts with ED at baseline: 1 PR and 13 SD (DCR 35%) according to RECIST; 2 CR, 2 PR and 14 SD (DCR 45%) according to immune related response criteria (irRC). PFS > 6 mths was observed for 13 pts with DCR by irRC (median 12 mths, range +7 to +45). Baseline LDH was the only independent prognostic baseline covariable (p < 0.001), and disease control by irRC was the strongest surrogate marker for OS (p < 0.001). Conclusions: Therapeutic vaccination with autologous mRNA electroporated DC combined with IFN-a2b is feasible, safe, and has anti-tumor activity in a subset of patients with advanced melanoma. Stratification by baseline LDH and the use of irRC seems appropriate in future studies with mRNA electroporated DC-vaccines and IFNa-2b. No significant financial relationships to disclose.
The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel.
Authors: S. Klang, N. Liebermann, S. Rizel, N. Ben-Baruch, S. Merling, L. Soussan-Gutman, R. Bugarini, C. Chao, S. Shak
Journal: Journal of Clinical Oncology (2010)

6075 Background: Recent Oncotype DX studies indicate that the recurrence score (RS) can identify certain N+/ER+ patients who may not benefit from chemotherapy. Clalit Health Services, Israel, was the first HMO outside the United States to reimburse the assay, and the RS has been used for treatment planning in N+/ER+ patients. We evaluated the relationship of the RS and actual adjuvant chemotherapy treatment in ER+ N+ patients. Methods: Eligible patients with micrometastases, 1, 2, 3, or 4 positive lymph nodes were identified between March 2006 and September, 2009. Claims data were reviewed to identify actual treatment administered. Results: 260 patients were eligible. 126 (48%) had micrometastases, 92 (35%) had 1 node, 36 (14%) had 2 nodes, 5 (2%) had three nodes, and 1 (<1%) had 4 nodes. Recurrence score results: Low RS group (RS<18), 59.2%; Intermediate RS group (RS 18-30), 34.6%; and High RS group (RS≥31), 6.2%. Chemotherapy (CT) was administered to 60 patients (23.1%) overall, and to 31% of the patients with 2-4 positive nodes. The proportions of patients who received CT increased with increasing RS group (Table). The proportions of patients who received CT increased with increasing nodal status group for patients with RS<18, but not for patients with RS 18-30 or for RS≥31. Conclusions: The recurrence score was used primarily in patient with micrometastases, 1, or 2 positive nodes. Treatment decisions in these node-positive breast cancer patients appear to be influenced by both the RS results and the number of nodes. Nodal status Number of patients who received CT divided by the total number of patients, and the associated percentage RS<18 RS 18-30 RS≥31 Total Nmic 1/73=1.4% 12/41=32.6% 11/12=91.7% 24/126=19.0% 1 N+ 7/59=14.8% 14/31=45.2% 2/2=100% 23/92=25.0% 2, 3, 4 N+ 4/22=18.2% 7/18=38.9% 2/2=100% 13/42=31.0% Total 12/154=22.2% 33/90=36.7% 15/16=93.8% 60/260=23.1% Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genomic Health, Teva Genomic Health, Teva
P0071 : Real-time measurements of tissue oxygen microtension as a marker of bile duct viability in liver transplantation
Authors: E. Navarro-Rodríguez, R. Ciria-Bru, M. Sanchez-Frias, J. Medina-Fernández, A.B. Gallardo-Herrera, M.D. Ayllon-Teran, S. Rufián-Peña, P. López-Cillero, J. Briceño-Delgado
Journal: Journal of Hepatology (2015)